Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. It focuses on cocrystal technology. Its products include NXP001, NXP002, and NXP004. The company was founded by Joanne Holland, Daniel Gooding, and David Tapolczay in 2008 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company